Jazz Pharmaceuticals plc (JAZZ) Presents at Wells Fargo 21st Annual Healthcare Conference TranscriptSeeking Alpha • 09/09/26
Ziihera® (zanidatamab-hrii) plus Chemotherapy Demonstrates Statistically Significant Overall Survival Benefit Versus Trastuzumab plus Chemotherapy in First-Line HER2+ Advanced GEAPRNewsWire • 08/31/26
Jazz Pharmaceuticals Announces Pricing of Upsized Private Offering of $1.1 Billion of 1.875% Exchangeable Senior Notes due 2032 and Concurrent Ordinary Share RepurchasesPRNewsWire • 08/27/26
JAZZ Secures FDA Nod for Expanded Use of Ziihera in Gastric CancerZacks Investment Research • 08/26/26
Jazz Pharmaceuticals Announces Private Offering of $1.0 Billion of Exchangeable Senior Notes due 2032 and Concurrent Ordinary Share RepurchasesPRNewsWire • 08/26/26
Jazz Pharmaceuticals plc (JAZZ) Discusses FDA Approval and Commercial Launch of ZIIHERA for First-Line HER2-Positive GEA TranscriptSeeking Alpha • 08/26/26
U.S. FDA Approves Ziihera® (zanidatamab-hrii) with and without Tislelizumab plus Chemotherapy in First-Line HER2+ Advanced Gastroesophageal AdenocarcinomaPRNewsWire • 08/25/26
Jazz Pharmaceuticals Bolsters Epilepsy Division With Actio Biosciences BuyoutSeeking Alpha • 08/12/26
Jazz Pharmaceuticals to acquire Actio Biosciences for $820 million, expanding rare epilepsy portfolioCNBC • 08/11/26
Unlocking Jazz (JAZZ) International Revenues: Trends, Surprises, and ProspectsZacks Investment Research • 08/10/26
Jazz Pharmaceuticals to Acquire Actio Biosciences, Expanding Rare Epilepsy PortfolioPRNewsWire • 08/10/26
Why Jazz Pharmaceuticals (JAZZ) is a Top Momentum Stock for the Long-TermZacks Investment Research • 08/07/26
JAZZ Q2 Earnings Miss, Sales Beat, Stock Jumps on Raised '26 ViewZacks Investment Research • 08/04/26
These Analysts Increase Their Forecasts On Jazz Pharmaceuticals Following Q2 ResultsBenzinga • 08/04/26
Compared to Estimates, Jazz (JAZZ) Q2 Earnings: A Look at Key MetricsZacks Investment Research • 08/04/26